TY - JOUR T1 - <strong>Fully hybrid 68Ga-DOTATOC PET/MRI </strong><strong>in NET patients: synergic value of 68Ga-DOTATOC PET and MRI </strong> JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 561 LP - 561 VL - 61 IS - supplement 1 AU - Paola Mapelli AU - Gabriele Ironi AU - Stefano Partelli AU - Federico Fallanca AU - Francesca Muffatti AU - Valentina Andreasi AU - Paola Scifo AU - Valentino Bettinardi AU - Riccardo Rigamonti AU - Annarita Savi AU - Luigi Gianolli AU - Massimo Falconi AU - Francesco De Cobelli AU - Maria Picchio Y1 - 2020/05/01 UR - http://jnm.snmjournals.org/content/61/supplement_1/561.abstract N2 - 561Purpose: Fully hybrid PET/MRI scanners represent and innovation in the field of molecular imaging; the simultaneous acquisition of 68Ga-DOTATOC PET and functional MRI has relevant implication in the field of Neuroendocrine Tumours (NETs). The aim of the present study is to evaluate the synergic value of fully hybrid 68Ga-DOTATOC PET/MRI in the management of NETs. Materials and Methods: Forty-three patients with diagnosis or imaging suspicion of NET underwent 68Ga-DOTATOC PET/MRI for staging (30 pts) or restaging (13 pts) purpose from September 2018 to November 2019. Whole-body PET/MRI scan started approximately 60 minutes after 68GA-DOTATOC injection, followed by a dedicated MRI protocol on the upper and/or lower abdomen. Using an axial LAVA-FLEX acquisition during contrast, two arterial phases and a portal venous phase before and after the injection of a gadolinium-based contrast agent have been performed. These sequences were followed by axial SSFSE and axial echo planar DWI. Axial and coronal breath-hold hepatobiliary phase (HBP) were finally performed. PET images were also acquired simultaneously to the diagnostic MRI. 68Ga-DOTATOC PET scans were analyzed by an experienced Nuclear Medicine Physician and the diagnostic MRI by an expert Radiologist. For each 68Ga-DOTATOC PET/MRI scan, an additional analysis combining PET and MRI findings (concordant and/or discordant) was performed. Results: Discordances between PET and MRI were observed in 7/43 pts (16.2%; 5 in the staging group and 2 in the restaging group). Diagnostic MRI (at abdominal level) could not detect extra-abdominal lesions detected by whole body 68Ga-DOTATOC PET (lung findings in 1/7 pts). In a MEN1 patient, both PET and MRI detected a major pancreatic lesion, with only PET identifying several additional uptakes within the pancreatic gland as site of additional NETs (histological examination confirmed multiple pancreatic NETs). In 3 staging patients, PET detected the presence of 68Ga-DOTATOC uptake within the pancreas, in correspondence of small lesions (&lt;8mm) not clearly identifiable on MRI images. Finally, MRI detected liver metastases not seen on 68Ga-DOTATOC PET (2/7 pts; 1 in the staging group and 1 in the restaging group). Conclusions: 68Ga-DOTATOC PET and MRI provide synergic information, in both staging and restaging phases of NETs patients. MRI confirmed its undisputed role in liver disease detection and monitoring. The major strength of PET is the ability to provide a whole-body assessment of receptor expression, also in small lesions hardly detected by MRI. ER -